FRANKLIN, Tenn.--(BUSINESS WIRE)--March 20, 2006--BioMimetic Therapeutics, Inc. announced today it has initiated three clinical trials to evaluate GEM OS1(TM) Bone Graft for use in foot and ankle fusion procedures and the treatment of unstable distal radius fractures. GEM OS1 is a unique bio-active drug-device combination product that combines a tissue growth factor, recombinant human Platelet-Derived Growth Factor (rhPDGF), one of the principal wound healing stimulators in the body, with a synthetic bone matrix, Beta-tricalcium phosphate (Beta-TCP). BioMimetic is leveraging the same combination drug-device technology for orthopedic applications as it utilized in its FDA approved product, GEM 21S(R) Growth-factor Enhanced Matrix for the treatment of periodontally related defects and gingival recession.
